Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: Systematic review

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Atsou, Kokuvi ^a,b   Chouaid, Christos ^a,b,c   Hejblum, Gilles ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DATA BASE; DISEASE EXACERBATION; DISEASE SEVERITY; EUROPE; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MORTALITY; PREVALENCE; STANDARDIZATION; SYSTEMATIC REVIEW; DISEASE COURSE; HOSPITALIZATION; META ANALYSIS; PATHOLOGY; REVIEW;

DISEASE PROGRESSION; EUROPE; HUMANS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 78651457782     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-7     Document Type: Article

References (90)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946. 10.1183/09031936.04.00014304, 15219010.
2. Hurd S, Pauwels R. Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Pulm Pharmacol Ther 2002, 15:353-355. 10.1006/pupt.2002.0381, 12220939.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442. 10.1371/journal.pmed.0030442, 1664601, 17132052.
4. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005, 294:1255-1259. 10.1001/jama.294.10.1255, 16160134.
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504. 10.1016/S0140-6736(96)07492-2, 9167458.
6. Bellamy D, Bouchard J, Henrichsen S, Johansson G, Langhammer A, Reid J, van Weel C, Buist S. International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006, 15:48-57. 10.1016/j.pcrj.2005.11.003, 16701758.
7. Société de Pneumologie de Langue Française [Recommendations of the Francophone Society of Pneumology for pulmonary rehabilitation in COPD] [Article in French]. Rev Mal Respir 2005, 22:696-704. Société de Pneumologie de Langue Française.
8. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750. 10.1016/S0140-6736(07)61377-4, 17765523.
9. Menezes AM, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG, . PLATINO team Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005, 366:1875-1881. 10.1016/S0140-6736(05)67632-5, 16310554, PLATINO team.
10. Eurostat Causes of death: Standardised death rate (per 100,000 inhabitants) (Annual Data). Eurostat., http://nui.epp.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_cd_asdr&lang=en
11. Jaén A, Ferrer A, Ormaza I, Rué M, Domingo C, Marín A. [Prevalence of chronic bronchitis, asthma and airflow limitation in an urban-industrial area of Catalonia] [Article in Spanish]. Arch Bronconeumol 1999, 35:122-128.
12. Marco Jordán L, Martín Berra JC, Corres Iñigo M, Luque Díez R, Zubillaga Garmendia G. [Chronic obstructive lung disease in the general population. An epidemiologic study performed in Guipúzcoa] [Article in Spanish]. Arch Bronconeumol 1998, 34:23-27.
13. Brotons B, Pérez JA, Sánchez-Toril F, Soriano S, Hernández J, Belenguer JL. [The prevalence of chronic obstructive pulmonary disease and asthma: a cross-sectional study] [Article in Spanish]. Arch Bronconeumol 1994, 30:149-152.
14. Piperno D, Bart F, Serrier P, Zureik M, Finkielsztejn L. [General practice patients at risk of chronic obstructive pulmonary disease: epidemiologic survey of 3,411 patients] [Article in French]. Presse Med 2005, 34:1617-1622. 10.1016/S0755-4982(05)84236-8, 16327699.
15. Cerveri I, Accordini S, Corsico A, Zoia MC, Carrozzi L, Cazzoletti L, Beccaria M, Marinoni A, Viegi G, de Marco R. Chronic cough and phlegm in young adults. Eur Respir J 2003, 22:413-417. 10.1183/09031936.03.00121103, 14516128.
16. Huchon GJ, Vergnenegre A, Neukirch F, Brami G, Roche N, Preux PM. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J 2002, 20:806-812. 10.1183/09031936.02.00042002, 12412668.
17. Cerveri I, Accordini S, Verlato G, Corsico A, Zoia MC, Casali L, Burney P, de Marco R. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 2001, 18:85-92. 10.1183/09031936.01.00087101, 11510810.
18. Cazzola M, Bettoncelli G, Sessa E, Cricelli C. Primary care of the patient with chronic obstructive pulmonary disease in Italy. Respir Med 2009, 103:582-588. 10.1016/j.rmed.2008.10.017, 19103479.
19. Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ, Studnicka M, Jensen RL, Buist AS. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest 2007, 131:29-36. 10.1378/chest.06-0365, 17218553.
20. Montnemery R, Nihlen U, Andersson M, Greiff L, Johannisson A, Nyberg P, Persson CG, Lofdahl CG. Obstructive airways diseases, smoking and use of inhaled corticosteroids in southern Sweden in 1992 and 2000. Int J Tuberc Lung Dis 2006, 10:490-498.
21. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999, 28:717-722. 10.1093/ije/28.4.717, 10480701.
22. Montnemery P, Adelroth E, Heuman K, Johannisson A, Johansson SA, Lindholm LH, Lundback B, Lofdahl CG. Prevalence of obstructive lung diseases and respiratory symptoms in southern Sweden. Respir Med 1998, 92:1337-1345. 10.1016/S0954-6111(98)90139-1, 10197227.
23. Lundback B, Nystrom L, Rosenhall L, Stjernberg N. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. Eur Respir J 1991, 4:257-266.
24. Miravitlles M, Soriano JB, Garcia-Rio F, Munoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Ancochea J. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009, 64:863-868. 10.1136/thx.2009.115725, 19553233.
25. Van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, Joos GF, Stricker BH, Brusselle GG. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest 2009, 135:368-377. 10.1378/chest.08-0684, 19201711.
26. Hansen JG, Pedersen L, Overvad K, Omland T, Jensen HK, Sørensen HT. The prevalence of chronic obstructive pulmonary disease among Danes aged 45-84 years: population-based study. COPD 2008, 5:347-352. 10.1080/15412550802522635, 19353348.
27. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax 2008, 63:402-407. 10.1136/thx.2007.085456, 18234906.
28. Roche N, Dalmay F, Perez T, Kuntz C, Vergnenegre A, Neukirch F, Giordanella JP, Huchon G. Impact of chronic airflow obstruction in a working population. Eur Respir J 2008, 31:1227-1233. 10.1183/09031936.00089607, 18216058.
29. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006, 61:1043-1047. 10.1136/thx.2006.064410, 2117062, 17040932.
30. Stavem K, Sandvik L, Erikssen J. Can Global Initiative for Chronic Obstructive Lung Disease stage 0 provide prognostic information on long-term mortality in men?. Chest 2006, 130:318-325. 10.1378/chest.130.2.318, 16899828.
31. Sichletidis L, Tsiotsios I, Gavriilidis A, Chloros D, Kottakis I, Daskalopoulou E, Konstantinidis T. Prevalence of chronic obstructive pulmonary disease and rhinitis in northern Greece. Respiration 2005, 72:270-277. 10.1159/000085368, 15942296.
32. Murtagh E, Heaney L, Gingles J, Shepherd R, Kee F, Patterson C, MacMahon J. Prevalence of obstructive lung disease in a general population sample: the NICECOPD study. Eur J Epidemiol 2005, 20:443-453. 10.1007/s10654-005-1248-8, 16080593.
33. Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N. Prevalence of COPD in Greece. Chest 2004, 125:892-900. 10.1378/chest.125.3.892, 15006947.
34. Hasselgren M, Arne M, Lindahl A, Janson S, Lundback B. Estimated prevalences of respiratory symptoms, asthma and chronic obstructive pulmonary disease related to detection rate in primary health care. Scand J Prim Health Care 2001, 19:54-57. 10.1080/028134301300034701, 11303549.
35. Peña VS, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, Viejo JL, Fernández-Fau L. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000, 118:981-989.
36. Viegi G, Pedreschi M, Pistelli F, Di Pede F, Baldacci S, Carrozzi L, Giuntini C. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest 2000, 117(Suppl 2):339-345. 10.1378/chest.117.5_suppl_2.339S, 10669672.
37. Dickinson JA, Meaker M, Searle M, Ratcliffe G. Screening older patients for obstructive airways disease in a semi-rural practice. Thorax 1999, 54:501-505. 10.1136/thx.54.6.501, 1745503, 10335003.
38. Renwick DS, Connolly MJ. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax 1996, 51:164-168. 10.1136/thx.51.2.164, 473027, 8711649.
39. Bakke PS, Baste V, Hanoa R, Gulsvik A. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax 1991, 46:863-870. 10.1136/thx.46.12.863, 463489, 1792631.
40. Peabody JW, Schau B, Lopez-Vidriero M, Vestbo J, Wade S, Iqbal A. COPD: a prevalence estimation model. Respirology 2005, 10:594-602. 10.1111/j.1440-1843.2005.00755.x, 16268912.
41. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001, 164:590-596.
42. Stang P, Lydick E, Silberman C, Kempel A, Keating ET. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 2000, 117(Suppl 2):354-359. 10.1378/chest.117.5_suppl_2.354S, 10669674.
43. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 152:S77-S121. American Thoracic Society.
44. The COPD Guidelines Group of the Standards of Care Committee of the BTS BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997, 52(Suppl 5):1-28. 1758399, 9039230, The COPD Guidelines Group of the Standards of Care Committee of the BTS.
45. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J, . on behalf of the European Respiratory Society Task Force Optimal assessment and management of chronic obstructive pulmonary disease (COPD): the European Respiratory Society Task Force. Eur Respir J 1995, 8:1398-1420. 10.1183/09031936.95.08081398, 7489808, on behalf of the European Respiratory Society Task Force.
46. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555. 10.1164/rccm.200703-456SO, 17507545.
47. Lindberg A, Bjerg-Backlund A, Ronmark E, Larsson LG, Lundback B. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking: report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2006, 100:264-272. 10.1016/j.rmed.2005.04.029, 15975774.
48. De Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004, 59:120-125. 10.1136/thorax.2003.011163, 1746950, 14760151.
49. Jansson SA, Andersson F, Borg S, Ericsson T, Jönsson E, Lundback B. Costs of COPD in Sweden according to disease severity. Chest 2002, 122:1994-2002. 10.1378/chest.122.6.1994, 12475838.
50. Von Hertzen L, Reunanen A, Impivaara O, Malkia E, Aromaa A. Airway obstruction in relation to symptoms in chronic respiratory disease: a nationally representative population study. Respir Med 2000, 94:356-363. 10.1053/rmed.1999.0715, 10845434.
51. Izquierdo JL, Barcina C, Jimenez J, Munoz M, Leal M. Study of the burden on patients with chronic obstructive pulmonary disease. Int J Clin Pract 2009, 63:87-97. 10.1111/j.1742-1241.2008.01936.x, 2705822, 19125996.
52. Hoogendoorn M, Feenstra TL, Schermer TR, Hesselink AE, Rutten-van Molken MP. Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Respir Med 2006, 100:83-86. 10.1016/j.rmed.2005.04.004, 15894477.
53. Detournay B, Pribil C, Fournier M, Housset B, Huchon G, Huas D, Godard P, Voinet C, Chanal I, Jourdanne C, Durand-Zaleski I. The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France. Value Health 2004, 7:168-174. 10.1111/j.1524-4733.2004.72329.x, 15164806.
54. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, Pride NB. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000, 55:789-794. 10.1136/thorax.55.9.789, 1745847, 10950900.
55. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:925-931. 1747235, 16055622.
56. Tsoumakidou M, Tzanakis N, Voulgaraki O, Mitrouska I, Chrysofakis G, Samiou M, Siafakas NM. Is there any correlation between the ATS, BTS, ERS and GOLD COPD's severity scales and the frequency of hospital admissions?. Respir Med 2004, 98:178-183. 10.1016/j.rmed.2003.09.011, 14971883.
57. Kornmann O, Beeh KM, Beier J, Geis UP, Ksoll M, Buhl R. Newly diagnosed chronic obstructive pulmonary disease: clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration 2003, 70:67-75. 10.1159/000068417, 12584394.
58. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003, 58:654-658. 10.1136/thorax.58.8.654, 1746769, 12885977.
59. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456. 10.1016/S0140-6736(03)12459-2, 12583942.
60. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003, 21:68-73. 10.1183/09031936.03.00013303, 12570111.
61. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C, Ronmark E, Lundback B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002, 96:700-708. 10.1053/rmed.2002.1334, 12243316.
62. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320:1297-1303. 10.1136/bmj.320.7245.1297, 27372, 10807619.
63. Effing T, Kerstjens H, van der Valk P, Zielhuis G, van der Palen J. (Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. Thorax 2009, 64:956-962. 10.1136/thx.2008.112243, 19736179.
64. Worth H, Schacher C, Dethlefsen U. Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial. Respir Res 2009, 10:69. 10.1186/1465-9921-10-69, 2720945, 19624838.
65. Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, van Schayck O, van Weel C. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 2009, 103:542-551. 10.1016/j.rmed.2008.11.003, 19138505.
66. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J 2006, 15:346-353.
67. Wilkinson TM, Donaldson GC, Johnston SL, Openshaw PJ, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:871-876. 10.1164/rccm.200509-1489OC, 16456141.
68. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003, 22:931-936. 10.1183/09031936.03.00038303, 14680081.
69. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1608-1613.
70. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008, 178:1139-1147. 10.1164/rccm.200801-145OC, 18723437.
71. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554. 10.1056/NEJMoa0805800, 18836213.
72. Calverley PM, Rennard S, Nelson HS, Karpel JP, Abbate EH, Stryszak P, Staudinger H. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008, 9:73. 10.1186/1465-9921-9-73, 2644301, 19014549.
73. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26. 10.1164/rccm.200707-973OC, 17916806.
74. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006, 27:547-555. 10.1183/09031936.06.00062705, 16507855.
75. Oostenbrink JB, Rutten-van Mölken MP, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004, 23:241-249. 10.1183/09031936.03.00083703, 14979498.
76. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003, 58:399-404. 10.1136/thorax.58.5.399, 1746668, 12728159.
77. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, Donaldson GC, Sullivan SD. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004, 7:153-167. 10.1111/j.1524-4733.2004.72318.x, 15164805.
78. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000, 117(Suppl):1-4. 10.1378/chest.117.2_suppl.1S, 10631186.
79. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003, 124:459-467. 10.1378/chest.124.2.459, 12907529.
80. Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia JL, Garau J. Mortality after hospitalization for COPD. Chest 2002, 121:1441-1448. 10.1378/chest.121.5.1441, 12006426.
81. Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E, Nieminen MM, Aine T, Bakke P, Janson C. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006, 7:109. 10.1186/1465-9921-7-109, 1560381, 16914029.
82. Arne M, Lisspers K, Stallberg B, Boman G, Hedenstrom H, Janson C, Emtner M. How often is diagnosis of COPD confirmed with spirometry?. Respir Med 2010, 104:550-556. 10.1016/j.rmed.2009.10.023, 19931443.
83. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, Wedzicha JA, Price D, Hyland ME. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009, 180:1189-1195. 10.1164/rccm.200902-0271OC, 19797160.
84. Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Antó JM, Agustí AG, Gómez FP, Rodríguez-Roisín R, Moons KG, Kessels AG, Held U. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009, 374:704-711. 10.1016/S0140-6736(09)61301-5, 19716962.
85. Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, Maltais F, Bourbeau JF, Goldstein RS, Balter M, O'Donnell D, Fitzgerald M. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008, 63:122-128. 10.1136/thx.2007.082636, 17702790.
86. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stat Rep 2001, 49:1-32.
87. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003, 58:388-393. 10.1136/thorax.58.5.388, 1746680, 12728157.
88. EQUATOR Network Library for health research reporting. EQUATOR Network., http://www.equator-network.org/resource-centre/library-of-health-research-reporting/
89. Loddenkemper R, Gibson GJ, Sibille Y. The burden of lung disease in Europe. European Lung White Book 2003, Lausanne, Switzerland: ERS Ltd.
90. Burney P, Suissa S, Soriano JB, Vollmer WM, Viegi G, Sullivan SD, Fabbri LM, Sin DD, Ernst P, Coultas D, Bourbeau J, Mapel DW, Weiss K, McLaughlin T, Price D, Sturkenboom MC, Taylor R, Hagan GW. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur Respir J 2003, 22(Suppl 43):41s-44s.